Saul N Faust

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8813619/publications.pdf

Version: 2024-02-01

175 papers 28,397 citations

50 h-index 155 g-index

198 all docs 198
docs citations

198 times ranked 43641 citing authors

#	Article	IF	CITATIONS
1	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	13.9	8,063
2	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
3	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
4	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
5	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of $ChAdOx1 nCoV-19 (AZD1222) vaccine$: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
7	Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis. New England Journal of Medicine, 2001, 345, 408-416.	13.9	704
8	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
9	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
10	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	6.3	519
11	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
12	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	6.3	430
13	Clinical spectrum and features of activated phosphoinositide 3-kinase δsyndrome: AÂlarge patient cohort study. Journal of Allergy and Clinical Immunology, 2017, 139, 597-606.e4.	1.5	377
14	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA - Journal of the American Medical Association, 2016, 316, 835.	3.8	263
15	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet, The, 2014, 384, 2123-2131.	6.3	247
16	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. The Lancet Child and Adolescent Health, 2021, 5, 133-141.	2.7	228
17	Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	2.9	224
18	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214

#	Article	IF	Citations
19	ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368.	3.7	196
20	Ribosomal Protein SA Haploinsufficiency in Humans with Isolated Congenital Asplenia. Science, 2013, 340, 976-978.	6.0	176
21	Children are not COVID-19 super spreaders: time to go back to school. Archives of Disease in Childhood, 2020, 105, 618-619.	1.0	169
22	Bone and Joint Infections. Pediatric Infectious Disease Journal, 2017, 36, 788-799.	1,1	165
23	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	6.3	161
24	Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Molecular Therapy, 2017, 25, 2104-2116.	3.7	149
25	Cephalosporinâ€3′â€diazeniumdiolates: Targeted NOâ€Donor Prodrugs for Dispersing Bacterial Biofilms. Angewandte Chemie - International Edition, 2012, 51, 9057-9060.	7.2	137
26	Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Frontiers in Immunology, 2018, 9, 543.	2.2	137
27	Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine, 2015, 33, 2015-2021.	1.7	130
28	Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age. Pediatric Infectious Disease Journal, 2010, 29, e80-e90.	1.1	114
29	<i>Pseudomonas aeruginosa</i> infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Review of Respiratory Medicine, 2016, 10, 685-697.	1.0	114
30	Prescribing for children $\hat{a} \in \text{``taste}$ and palatability affect adherence to antibiotics: a review. Archives of Disease in Childhood, 2012, 97, 293-297.	1.0	111
31	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	1.9	110
32	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight, 2017, 2, .	2.3	109
33	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, The. 2022. 22. 1131-1141.	4.6	99
34	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 _B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	1.9	96
35	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <ip. falciparum<="" i="">Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. Journal of Infectious Diseases, 2016, 213, 1743-1751.</ip.>	1.9	95
36	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine, 2022, 44, 101262.	3.2	87

#	Article	IF	CITATIONS
37	Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. Critical Care Medicine, 2001, 29, S62-S67.	0.4	85
38	Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiology Letters, 2017, 364, .	0.7	85
39	Managing bone and joint infection in children. Archives of Disease in Childhood, 2012, 97, 545-553.	1.0	83
40	New approaches to the treatment of biofilm-related infections. Journal of Infection, 2014, 69, S47-S52.	1.7	82
41	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
42	Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: A retrospective study*. Critical Care Medicine, 2004, 32, 1777-1780.	0.4	76
43	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2021, 2, 701-719.e19.	2.2	73
44	Inflammatory phenotyping predicts clinical outcome in COVID-19. Respiratory Research, 2020, 21, 245.	1.4	72
45	Current methods for capsular typing of Streptococcus pneumoniae. Journal of Microbiological Methods, 2015, 113, 41-49.	0.7	70
46	Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine, 2011, 29, 4400-4404.	1.7	69
47	Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 404-414.	2.7	69
48	The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine, 2017, 35, 1293-1298.	1.7	68
49	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. Journal of Infection, 2015, 71, 43-52.	1.7	61
50	Extremes of Age Are Associated with Indeterminate QuantiFERON-TB Gold Assay Results. Journal of Clinical Microbiology, 2014, 52, 2694-2697.	1.8	60
51	Non-alcoholic fatty liver disease and childhood obesity. Archives of Disease in Childhood, 2021, 106, 3-8.	1.0	57
52	Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2021, 326, 1713.	3.8	57
53	Emergency management of meningococcal disease: eight years on. Archives of Disease in Childhood, 2007, 92, 283-286.	1.0	56
54	Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. The Lancet Child and Adolescent Health, 2018, 2, 338-349.	2.7	51

#	Article	IF	CITATIONS
55	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	2.9	51
56	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 2022, 3, 552-564.	5.7	51
57	Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?. Current Opinion in Infectious Diseases, 2008, 21, 258-262.	1.3	50
58	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. FASEB Journal, 2012, 26, 907-916.	0.2	50
59	COVID-19 in children: current evidence and key questions. Current Opinion in Infectious Diseases, 2020, 33, 540-547.	1.3	49
60	Corticosteroids and infliximab impair the performance of interferon- \hat{l}^3 release assays used for diagnosis of latent tuberculosis. Thorax, 2017, 72, 946-949.	2.7	43
61	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial Journal of Infection, 2022, 84, 795-813.	1.7	43
62	Pronounced Metabolic Changes in Adaptation to Biofilm Growth by Streptococcus pneumoniae. PLoS ONE, 2014, 9, e107015.	1.1	42
63	Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization. Clinical Infectious Diseases, 2020, 71, 403-411.	2.9	40
64	Nasal self-swabbing for estimating the prevalence of Staphylococcus aureus in the community. Journal of Medical Microbiology, 2013, 62, 437-440.	0.7	39
65	Intracellular residency of Staphylococcus aureus within mast cells in nasal polyps: A novel observation. Journal of Allergy and Clinical Immunology, 2015, 135, 1648-1651.e5.	1.5	39
66	Predictors of immune response and reactogenicity to ASO3B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine, 2011, 29, 7913-7919.	1.7	35
67	13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin, 2011, 7, 1012-1018.	2.4	35
68	Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 117-125.	1.3	35
69	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390.	1.6	34
70	Monovalent inactivated split-virion ASO3-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Review of Vaccines, 2010, 9, 1385-1398.	2.0	33
71	Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies. Scientific Reports, 2016, 6, 35842.	1.6	33
72	Disseminated intravascular coagulation and purpura fulminans secondary to infection. Best Practice and Research in Clinical Haematology, 2000, 13, 179-197.	0.7	32

#	Article	IF	Citations
73	Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2021, 398, 1417-1426.	6.3	32
74	Primary ciliary dyskinesia ciliated airwayÂcells show increased susceptibility to <i>Haemophilus influenzae</i> biofilm formation. European Respiratory Journal, 2017, 50, 1700612.	3.1	31
75	Platelet and soluble CD40L in meningococcal sepsis. Intensive Care Medicine, 2006, 32, 1432-1437.	3.9	30
76	Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. Emerging Infectious Diseases, 2010, 16, 154-155.	2.0	30
77	Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine. JAMA Network Open, 2021, 4, e2128652.	2.8	29
78	Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase \hat{l} syndrome. Clinical Immunology, 2016, 171, 38-40.	1.4	28
79	Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia (Nathan Qld) Tj ETQq1	10.7843 2.5	14 rgBT /Ov
80	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ, The, 2015, 350, h1554-h1554.	3.0	27
81	Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic Tolerance. Antimicrobial Agents and Chemotherapy, 2016, 60, 2456-2466.	1.4	27
82	Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort. Clinical and Translational Immunology, 2017, 6, e155.	1.7	27
83	Cephalosporin-3′-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	26
84	Investigating <i>Bordetella pertussis </i> colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open, 2017, 7, e018594.	0.8	26
85	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children in Summer Schools Applying Stringent Control Measures in Barcelona, Spain. Clinical Infectious Diseases, 2022, 74, 66-73.	2.9	26
86	Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. Microbial Genomics, 2017, 3, e000119.	1.0	26
87	Precision Molecular Diagnosis Defines Specific Therapy in Combined Immunodeficiency with Megaloblastic Anemia Secondary to MTHFD1 Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1160-1166.e10.	2.0	25
88	H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. Clinical Infectious Diseases, 2012, 54, 661-669.	2.9	24
89	Paper-based colorimetric enzyme linked immunosorbent assay fabricated by laser induced forward transfer. Biomicrofluidics, 2014, 8, 036502.	1.2	24
90	Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged <2 Years: Expert Recommendations on How to Address This Issue. Clinical Infectious Diseases, 2015, 60, 912-918.	2.9	24

#	Article	IF	CITATIONS
91	Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. Journal of Allergy and Clinical Immunology, 2018, 141, 1479-1482.e6.	1.5	24
92	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. Pediatrics, 2016, 138, .	1.0	22
93	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology, 2021, 12, 694759.	2.2	22
94	Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine. PLoS ONE, 2013, 8, e64731.	1.1	21
95	Cephalosporin-NO-donor prodrug PYRRO-C3D shows β-lactam - mediated activity against Streptococcus pneumoniae biofilms. Nitric Oxide - Biology and Chemistry, 2017, 65, 43-49.	1.2	21
96	Lupus, vaccinations and COVID-19: What we know now. Lupus, 2021, 30, 1541-1552.	0.8	21
97	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clinical Microbiology and Infection, 2022, 28, 1649.e1-1649.e8.	2.8	20
98	Suspected sepsis: summary of NICE guidance. BMJ, The, 2016, 354, i4030.	3.0	19
99	Lyme disease: summary of NICE guidance. BMJ: British Medical Journal, 2018, 361, k1261.	2.4	19
100	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. Health Technology Assessment, 2017, 21, 1-164.	1.3	19
101	Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Review of Vaccines, 2012, 11, 889-902.	2.0	18
102	Stroke in paediatric pneumococcal meningitis: a cross-sectional population-based study. Archives of Disease in Childhood, 2013, 98, 647-649.	1.0	18
103	Discovery of Cephalosporin-3′-Diazeniumdiolates That Show Dual Antibacterial and Antibiofilm Effects against <i>Pseudomonas aeruginosa</i> Clinical Cystic Fibrosis Isolates and Efficacy in a Murine Respiratory Infection Model. ACS Infectious Diseases, 2020, 6, 1460-1479.	1.8	18
104	Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics, 2018, 142, .	1.0	17
105	Clinical Presentation of Influenza in Children 6 to 35 Months of Age. Pediatric Infectious Disease Journal, 2019, 38, 866-872.	1.1	17
106	RSV: perspectives to strengthen the need for protection in all infants. Emerging Themes in Epidemiology, 2021, 18, 15.	1.2	16
107	Opa Protein Repertoires of Disease-Causing and Carried Meningococci. Journal of Clinical Microbiology, 2008, 46, 3033-3041.	1.8	15
108	Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: The role of activated protein C in severe sepsis. Critical Care Medicine, 2001, 29, S75-S77.	0.4	14

#	Article	IF	CITATIONS
109	Sleeping Sickness in Brothers in London. Pediatric Infectious Disease Journal, 2004, 23, 879-881.	1.1	14
110	Ciliated Cultures From Patients With Primary Ciliary Dyskinesia Produce Nitric Oxide in Response to Haemophilus influenzae Infection and Proinflammatory Cytokines. Chest, 2014, 145, 668-669.	0.4	14
111	Fluarix quadrivalent vaccine for influenza. Expert Review of Vaccines, 2015, 14, 1055-1063.	2.0	14
112	POLYMORPHISMS IN PARP, IL1B, IL4, IL10, C1INH, DEFB1, AND DEFA4 IN MENINGOCOCCAL DISEASE IN THREE POPULATIONS. Shock, 2010, 34, 17-22.	1.0	13
113	Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis. Vaccine, 2013, 31, 3187-3190.	1.7	13
114	Environmental temperature impacts on the performance of QuantiFERON-TB Gold In-Tube assays. Journal of Infection, 2015, 71, 276-280.	1.7	13
115	Density Distribution of Pharyngeal Carriage of Meningococcus in Healthy Young Adults. Pediatric Infectious Disease Journal, 2016, 35, 1080-1085.	1.1	13
116	Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the <scp>UK</scp> towards participation in clinical trials and routine implementation. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 330-340.	1.3	13
117	Multi-Excitation Raman Spectroscopy for Label-Free, Strain-Level Characterization of Bacterial Pathogens in Artificial Sputum Media. Analytical Chemistry, 2022, 94, 669-677.	3.2	13
118	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine, 2018, 36, 2300-2306.	1.7	12
119	Immune reconstitution in children following chemotherapy for acute leukemia. EJHaem, 2020, 1, 142-151.	0.4	12
120	Experts' opinion for improving global adolescent vaccination rates: a call to action. European Journal of Pediatrics, 2020, 179, 547-553.	1.3	12
121	Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. BMJ Open, 2021, 11, e043012.	0.8	12
122	COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. BMJ Open, 2021, 11, e044899.	0.8	12
123	Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae. Microbial Genomics, $2018, 4, .$	1.0	12
124	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. PLoS ONE, 2014, 9, e91413.	1.1	12
125	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. Journal of Infection, 2022, 85, 306-317.	1.7	12
126	â€~Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open, 2020, 10, e037358.	0.8	11

#	Article	IF	CITATIONS
127	OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH GROUP A STREPTOCOCCAL INFECTION. Pediatric Infectious Disease Journal, 2007, 26, 358-359.	1.1	10
128	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomised controlled Trial (CAP-IT). BMJ Open, 2019, 9, e029875.	0.8	10
129	D-methionine interferes with non-typeable Haemophilus influenzae peptidoglycan synthesis during growth and biofilm formation. Microbiology (United Kingdom), 2017, 163, 1093-1104.	0.7	10
130	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. Pediatric Research, 2023, 93, 207-216.	1.1	10
131	Administration of ASO3B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged <3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. Clinical Infectious Diseases, 2014, 58, 181-187.	2.9	9
132	Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 172-180.	4.6	9
133	Mutations in <i>RPSA</i> and <i>NKX2â€3</i> link development of the spleen and intestinal vasculature. Human Mutation, 2020, 41, 196-202.	1.1	9
134	Parallel Evolution in Streptococcus pneumoniae Biofilms. Genome Biology and Evolution, 2016, 8, 1316-1326.	1.1	8
135	Comparative Genomics of Carriage and Disease Isolates of <i>Streptococcus pneumoniae </i> Serotype 22F Reveals Lineage-Specific Divergence and Niche Adaptation. Genome Biology and Evolution, 2016, 8, 1243-1251.	1.1	8
136	Paediatric research in the times of COVID-19. Pediatric Research, 2021, 90, 267-271.	1.1	8
137	Varicella Zoster Virus Central Nervous System Immune Reconstitution Inflammatory Syndrome Presenting in a Child. Pediatric Infectious Disease Journal, 2013, 32, 1283-1284.	1.1	7
138	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. Clinical Infectious Diseases, 2020, 71, 1271-1280.	2.9	7
139	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. Science Translational Medicine, $2021, 13, \ldots$	5.8	7
140	Development of X-ray micro-focus computed tomography to image and quantify biofilms in central venous catheter models in vitro. Microbiology (United Kingdom), 2016, 162, 1629-1640.	0.7	7
141	Protocol for a controlled human infection with genetically modified (i> Neisseria lactamica (i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. BMJ Open, 2019, 9, e026544.	0.8	6
142	Expediting clinical trials in a pandemic. BMJ: British Medical Journal, 2009, 339, b4652-b4652.	2.4	6
143	Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT. Health Technology Assessment, 2021, 25, 1-72.	1.3	6
144	Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial. BMJ Open, 2022, 12, e047490.	0.8	6

#	Article	IF	CITATIONS
145	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. Pediatric Infectious Disease Journal, 2013, 32, 675-681.	1.1	5
146	High frequency of paediatric facial nerve palsy due to Lyme disease in a geographically endemic region. International Journal of Pediatric Otorhinolaryngology, 2020, 132, 109905.	0.4	5
147	Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing study. Journal of Medical Microbiology, 2018, 67, 1096-1108.	0.7	5
148	Clostridium difficile in Children: A Review of Existing and Recently Uncovered Evidence. Advances in Experimental Medicine and Biology, 2013, 764, 57-72.	0.8	4
149	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLoS ONE, 2016, 11, e0155059.	1.1	4
150	Microbial epidemiology and carriage studies for the evaluation of vaccines. Journal of Medical Microbiology, 2019, 68, 1408-1418.	0.7	4
151	Empirical antibiotics for suspected early neonatal sepsis. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2012, 97, F75.1-F75.	1.4	3
152	Evidence Base for the Use of Corticosteroids in Septic Shock in Children. Critical Care Medicine, 2014, 42, e83-e84.	0.4	3
153	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. Journal of Immunology Research, 2015, 2015, 1-3.	0.9	3
154	Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatrics, 2019, 19, 50.	0.7	3
155	INFECTIOUS PURPURA FULMINANS: CAUTION NEEDED IN THE USE OF PROTEIN C. British Journal of Haematology, 1999, 106, 253-253.	1.2	3
156	Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2. Frontiers in Medical Technology, 2021, 3, 729658.	1.3	3
157	The Effect of Haematocrit on Measurement of the Mid-Infrared Refractive Index of Plasma in Whole Blood. Biosensors, 2021, 11, 417.	2.3	3
158	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. Clinical Microbiology and Infection, 2022, 28, 1238-1244.	2.8	3
159	Congenital syphilis presenting with liver lesions. International Journal of STD and AIDS, 2019, 30, 82-85.	0.5	2
160	Diagnosis and treatment of biofilm infections in children. Current Opinion in Infectious Diseases, 2019, 32, 505-509.	1.3	2
161	Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine, 2020, 38, 5718-5725.	1.7	2
162	Developmental assessment: practice makes perfect. Archives of Disease in Childhood, 2007, 92, 278-278.	1.0	1

#	Article	IF	Citations
163	Linezolid an Oral Treatment Option for Staphylococcal Liver Abscess in Chronic Granulomatous Disease. Pediatric Infectious Disease Journal, 2009, 28, 1036-1037.	1.1	1
164	Picture of the Monthâ€"Quiz Case. JAMA Pediatrics, 2013, 167, 483.	3.3	1
165	Respiratory tract infection associated with seizures. BMJ, The, 2015, 351, h4659.	3.0	1
166	Purpura Fulminans. , 2009, , 45-55.		1
167	Incidental findings in UK healthy volunteers screened for a COVIDâ€19 vaccine trial. Clinical and Translational Science, 2021, , .	1.5	1
168	Phase I studies: the role of publicly funded academic-healthcare partnerships. BMJ, The, 2015, 351, h3889.	3.0	0
169	Authors' reply to Eisenhut. BMJ, The, 2016, 355, i5787.	3.0	0
170	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine, 2016, 34, 6350-6357.	1.7	0
171	Problem-solving in clinical practice: Persisting respiratory distress in a premature infant. Archives of Disease in Childhood: Education and Practice Edition, 2020, 106, edpract-2019-317757.	0.3	0
172	Mycotic aneurysm presenting as hip pain and severe anaemia. Archives of Disease in Childhood, 2021, 106, archdischild-2021-321632.	1.0	0
173	P051â€fSymptoms of COVID-19 and anxiety levels in adult patients receiving b-and ts-DMARDS using an online reporting system. Rheumatology, 2021, 60, .	0.9	0
174	HIV-1 Infection in Children: Current Practice and Future Predictions. Advances in Experimental Medicine and Biology, 2004, 549, 135-148.	0.8	0
175	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. , 2018, , 18-32.		0